Orthofix (NSDQ:OFIX) said last week it is investing $1.3 million into the Musculoskeletal Transplant Foundation through a collaborative agreement to support the procurement and installation of equipment and tech at MTF’s Edison, N.J. facilities.
Lewisville, Texas-based Orthofix has maintained a collaborative agreement with MTF since 2008 to support the commercialization of its Trinity Evolution and Trinity Elite allograft matrices. Orthofix maintains the marketing rights to the product, while MTF sources, processes, packages and supplies them in allograft tissue form.
The new agreement will expand tissue processing and storage for both the Trinity Evolution and Trinity Elite at MTF’s storage facilities, and extends the existing agreement between the companies by 2 years, now through 2025, according to an SEC filing.
Last September, Orthofix said results from a study of its Trinity Evolution cellular bone allograft reported joint fusion rates above 85% after 1 year. The study was published online in the Foot & Ankle International journal.
The 92-patient trial is the largest safety and effectiveness trial to date for the graft, according to the company. A total of 153 foot and ankle fusion procedures were analyzed by the study, with a primary endpoint of successful fusion based on CT scan and radiograph review through an independent lab, the company said.
The study reported fusion rates of 81.1% at 6 months and 86.8% at 12 months, and reported comorbid factors associated with fusion failure did not have a negative events. No serious adverse events were reported.